Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
Monday, March 23, 2026 1 min read
Key Takeaway: Pfizer and Valneva have reported positive topline results from the Phase 3 VALOR trial for their Lyme disease vaccine candidate, PF-07307405. The vaccine demonstrated an efficacy of 73.2% in reducing Lyme disease rates from 28 days after the fourth dose. This promising outcome highlights the potential of the vaccine in preventing Lyme disease among outdoor enthusiasts.
Market Sentiment Analysis
POSITIVE FACTORS
The vaccine candidate shows a strong efficacy of 73.2%.
The results are from a Phase 3 clinical trial, indicating advanced testing.
The vaccine targets Lyme disease, a significant public health concern.
Full Press Release Details
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for Outdoor Recreationists” clinical trial (NCT05477524) of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 (LB6V, formerly known as VLA15) demonstrating: In the pre-specified analyses: Efficacy of 73.2% from 28 days post-dose 4 (season 2) in reducing the rate of confir
Frequently Asked Questions
What is the efficacy of the Lyme disease vaccine candidate?
The vaccine candidate demonstrated an efficacy of 73.2% in the Phase 3 trial.
What is the name of the Lyme disease vaccine candidate?
The vaccine candidate is named PF-07307405, also known as LB6V.
What phase is the VALOR trial for the Lyme vaccine?
The VALOR trial is a Phase 3 clinical trial.
Who are the developers of the Lyme disease vaccine?